Table 1. Clinical data of the overall study population and the subgroups.
| Parameter | Overall population (N = 1,715) | Bioimpedance (N = 1,682) | C-Peptide data (N = 1,632) | HEC (N = 518) | MRS (N = 375) | MRI (N = 357) | IVGTT (N = 314) |
|---|---|---|---|---|---|---|---|
| N (women/men) | 1,122/593 | 1,105/577 | 1,072/560 | 274/244 | 238/137 | 222/135 | 180/134 |
| Age (y) | 39 ± 12 | 39 ± 12 | 39 ± 12 | 40 ± 12 | 45 ± 12 | 45 ± 12 | 45 ± 11 |
| BMI (kg/m²) | 30.0 ± 9.1 | 29.9 ± 8.9 | 30.2 ± 9.2 | 27.3 ± 5.7 | 30.1 ± 5.1 | 30.0 ± 5.3 | 29.4 ± 5.7 |
| NGT/IFG/IGT/IFG+IGT | 1,211/194/162/148 | 1,193/189/166/134 | 1,148/187/153/144 | 397/40/48/33 | 236/50/48/41 | 225/43/49/40 | 210/32/43/29 |
| Glucose, fasting (mmol/L) | 5.14 ± 0.55 | 5.13 ± 0.55 | 5.14 ± 0.56 | 5.02 ± 0.53 | 5.26 ± 0.50 | 5.23 ± 0.50 | 5.18 ± 0.49 |
| 2-h Glucose (mmol/L) | 6.34 ± 1.65 | 6.34 ± 1.64 | 6.36 ± 1.64 | 6.17 ± 1.70 | 6.93 ± 1.54 | 6.92 ± 1.58 | 6.77 ± 1.66 |
| ISI, OGTT (x 1019 L2 x mol-2) | 15.5 ± 10.7 | 15.7 ± 10.7 | 15.5 ± 10.8 | 18.2 ± 11.2 | 12.3 ± 6.7 | 12.6 ± 6.9 | 14.0 ± 7.9 |
| Body fat content (%) | - | 32.4 ± 12.0 | 32.4 ± 12.0 | 28.2 ± 9.7 | 33.7 ± 9.2 | 33.0 ± 8.9 | 31.8 ± 8.9 |
| AUCIns0-30/AUCGlc0-30 (x 10−9) | - | - | 43.8 ± 32.4 | 37.2 ± 24.8 | 43.1 ± 27.1 | 42.3 ± 27.2 | 40.6 ± 24.9 |
| AUCC-Pep0-120/AUCGlc0-120 (x 10−9) | - | - | 321 ± 104 | 311 ± 97 | 306 ± 87 | 306 ± 90 | 307 ± 92 |
| ISI, HEC (x 106 L x kg-1 x min-1) | - | - | - | 0.084 ± 0.052 | - | - | 0.069 ± 0.041 |
| IHL (% signal) | - | - | - | - | 5.99 ± 6.49 | 5.96 ± 6.46 | - |
| TAT (% body weight) | - | - | - | - | - | 30.5 ± 9.1 | - |
| VAT (% body weight) | - | - | - | - | - | 3.33 ± 1.70 | - |
| AIR (pmol/L) | - | - | - | - | - | - | 933 ± 629 |
Data are given as counts or means ±SD. AIR—acute insulin response; AUC—area under the curve; BMI—body mass index; C-Pep—C-peptide; Glc—glucose; HEC—hyperinsulinaemic-euglycaemic clamp; IFG—impaired fasting glycaemia; IGT—impaired glucose tolerance; IHL—intrahepatic lipids; Ins—insulin; ISI—insulin sensitivity index; IVGTT—intravenous glucose tolerance test; MRI—magnetic resonance imaging; MRS—magnetic resonance spectroscopy; NGT—normal glucose tolerance; OGTT—oral glucose tolerance test; TAT—total adipose tissue; VAT—visceral adipose tissue